Continuing Education Activity

Pediatric depression includes major depressive disorder (MDD), disruptive mood dysregulation disorder, persistent depressive disorder, and unspecified depressive disorder. Among these, MDD is a leading cause of disability in adolescents in this age group. The etiology is multifactorial, involving genetic, environmental, and neurobiological risk factors that contribute to depression in children and adolescents. Screening is recommended for adolescents aged 12 to 18 with validated tools, and a comprehensive evaluation is essential for accurate diagnosis. Diagnosis requires a thorough clinical evaluation and differentiation from other conditions, such as attention-deficit/hyperactivity disorder, anxiety, and medical illnesses that mimic depressive symptoms. Treatment aims for complete remission and functional recovery through a biopsychosocial approach, combining psychotherapy (first-line for mild-to-moderate cases) and pharmacotherapy. Prevention strategies encompass school-based programs, family interventions, and policy initiatives designed to support healthy development.

This activity focuses on the latest evidence-based strategies for identifying, diagnosing, and managing pediatric depression, with an emphasis on early intervention and improving long-term outcomes. This activity highlights the role of validated screening tools, structured clinical interviews, and standardized assessment scales in enhancing diagnostic accuracy across various care settings. This activity also explores established and emerging treatment modalities, including pharmacologic interventions, digital health tools, and single-session therapies, providing clinicians with practical approaches to individualized care. This activity further examines novel research findings that inform prevention strategies aimed at reducing the incidence and severity of depressive disorders in youth. This activity highlights the importance of interprofessional collaboration among healthcare providers in delivering comprehensive, developmentally appropriate care.

Objectives:

• Identify the clinical features and diagnostic criteria of major depressive disorder in children and adolescents according to DSM-5 guidelines.
• Implement evidence-based treatment plans that integrate pharmacological, psychotherapeutic, and psychosocial interventions to optimize patient outcomes.
• Select appropriate pharmacological agents, such as selective serotonin reuptake inhibitors, based on patient age, symptom severity, safety profile, and response history.
• Collaborate with interprofessional healthcare teams to support comprehensive care, ensuring continuity and sustained mental health recovery.

Access free multiple choice questions on this topic.

Introduction

Depressive disorders, as defined in the Diagnostic and Statistical Manual of Mental Disorders, 5th ed. (DSM–5), include major depressive disorder (MDD), disruptive mood dysregulation disorder (DMDD), persistent depressive disorder (PDD, also known as dysthymia), and unspecified depressive disorder.

MDD remains the leading cause of disability among adolescents aged 10 to 19 (World Health Organization [WHO], 2014). Suicide is the third leading cause of death in this age group, with adolescent depression being a significant risk factor. Compared with matched controls, adolescents with depression report significantly more stressful life events in the year preceding the onset of symptoms.[1]

Etiology

The etiology of depression is multifactorial and complex, resulting from interactions between biological vulnerabilities and environmental factors.

Genes and Heritability

Genetic predisposition plays a crucial role in developing pediatric depression. Twin studies estimate heritability rates of 40% to 50%, with higher concordance observed in monozygotic twins. A recent genome-wide association study identified polygenic risk scores associated with early-onset depression, especially among individuals exposed to childhood adversity.[2] Moreover, polymorphisms in the serotonin transporter gene (5-HTTLPR) have been associated with increased depression risk, particularly when combined with environmental stressors.[3] A global study identified 300 new genetic variants related to depression, underscoring the importance of genetic predisposition in its development.[4]

Psychosocial Risk Factors

Stressful life events frequently precede the onset and recurrence of depressive episodes in adolescents, particularly among females.[5] However, not all children exposed to adversity develop depression, highlighting the role of individual resilience. Common psychosocial stressors include parental conflict, bullying, peer rejection, academic failure, and early exposure to trauma.[6]

Cognitive Risk Factors

Adolescents with depression often display cognitive biases, such as negative attentional and memory biases. They are more likely to recall negative information and have difficulty disengaging from distressing thoughts.[7][8] Additionally, a poor perception of competence and confidence,[9][10] along with maladaptive rumination, characterized by an excessive focus on distressing emotions, has been associated with the onset, severity, and persistence of depression.[11][12]

Additional Factors

• Sleep disturbances: Adolescents with depression often exhibit sleep abnormalities, including reduced sleep efficiency, prolonged sleep onset latency, increased frontal slow-wave activity, shortened rapid eye movement (REM) latency, and elevated REM density.[13][14][15]

• Comorbid medical conditions: Depression commonly co-occurs with chronic medical conditions such as epilepsy, type 1 diabetes, and autoimmune disorders, which can complicate both diagnosis and management.[16]

• Anxiety disorders, obsessive-compulsive disorder (OCD), and posttraumatic stress disorder (PTSD) frequently co-occur with pediatric depression, significantly affecting treatment response and overall prognosis.[17]

• Certain medications: Medications such as corticosteroids, interferons, mefloquine, progestin-releasing implanted contraceptives, and propranolol have been associated with an increased risk of depression.[18][19]

• Substance use: Early use of alcohol and cannabis has been associated with an increased risk of depressive episodes in adolescents, especially those with a family history of vulnerability.[20]

• Digital media use: Pervasive use of digital media has been associated with mental health concerns among youth. A meta-analysis by Keles and Idsoe reported a small but significant link between social media use and depression in adolescents. Notably, problematic social media use showed a moderate association with depressive symptoms, underscoring the importance of monitoring and providing guidance on digital media consumption.[21]

• Parental mental health: Children of parents with depression face an increased risk of developing depressive and anxiety disorders. Interventions focused on improving family dynamics and parental mental health have demonstrated potential in reducing this risk. Research highlights the critical importance of addressing parental mental health to help prevent depression in offspring.[22][23][24]

• Birth order: A comprehensive review by Franklin and Higgs et al involving nearly 182,500 cases found that firstborn and only children are more likely to develop anxiety and depression by age 8 compared to later-born children. This finding adds a new dimension to understanding risk factors for childhood depression.[Franklin B, et al. Firstborn Children and Only Children More Likely to Have Anxiety and Depression Than Later-Born Children. Epic Research. Oct 15, 2024]

Epidemiology

The annual incidence of pediatric depression is approximately 1% to 2% at age 13, rising to 3% to 7% by age 15.[25][21] Although the gender distribution is equal during childhood, prevalence becomes twice as high in females after puberty.[26][27] Research indicates that adolescents in low- and middle-income countries experience higher rates of depression compared to their peers in high-income countries, with prevalence ranging from 10% to 13% in boys and 12% to 18% in girls.[28][29]

History and Physical

DSM-5 Criteria for Diagnosing Depression in the Pediatric Population

Diagnosis requires the presence of at least 5 of the following symptoms during the same 2-week period, representing a change from an individual's previous functioning. At least 1 of the symptoms must be either depressed mood or loss of interest or pleasure. The symptoms must not be attributable to another medical condition.

• Persistent feelings of depression or irritability throughout most of the day, almost daily, as reported by the child (for example, the child expresses feelings of sadness, emptiness, or hopelessness) or noticed by others (for example, the child appears sad).
• A significant decrease in interest or pleasure in activities most of the day, nearly every day, as indicated by self-reporting or observation.
• Failure to achieve expected weight gain or significant weight loss without dieting, or a notable increase or decrease in appetite nearly every day.
• Lack of sleep (insomnia) or excessive sleeping (hypersomnia), which occurs almost every day.
• Psychomotor agitation or retardation nearly every day, observable by others (not just subjective feelings of restlessness).
• Fatigue or loss of energy nearly every day.
• Feelings of worthlessness or excessive or inappropriate guilt (which may be delusional) nearly every day, not merely guilt about being sick.
• Diminished ability to think, concentrate, or make decisions, occurring almost every day, as reported by the individual or observed by others.
• Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a specific plan, a suicide attempt, or a definite plan for suicide.

The illness causes clinically significant distress or impairment in one or more of the following areas—social, occupational, or other important areas of functioning. The depressive episode is not attributable to the physiological effects of a substance or another medical condition. The MDD episode cannot be better explained by schizoaffective disorder, schizophrenia, schizophreniform disorder, delusional disorder, or other specified or unspecified schizophrenia spectrum and other psychotic disorders. There is no history of manic or hypomanic episodes.

Clinical Presentation

Childhood depression often manifests differently from adult depression, necessitating careful attention to its distinct features.

• Emotional symptoms: Children may exhibit persistent sadness, irritability, or mood swings.
• Cognitive symptoms: Children may struggle with concentration, experience indecisiveness, and hold negative self-perceptions.
• Physical symptoms: Frequent somatic complaints, such as headaches or stomachaches, can be prevalent.
• Behavioral symptoms: Signs include social withdrawal, loss of interest in previously enjoyed activities, increased irritability, and noticeable changes in academic performance.

Evaluation

The United States Preventive Services Task Force (USPSTF) recommends screening for MDD in adolescents aged 12 to 18.[30] 

Screening Tools

Validated instruments such as the Children’s Depression Inventory (CDI) and the Patient Health Questionnaire for Adolescents (PHQ-A) are essential for initial screening. Commonly used, validated screening tools in primary care settings include:[31]

• Pediatric symptom checklist-17: A score of 5 or higher on the internalizing (I) subscale suggests the presence of internalizing disorders, such as depression.
• Mood and Feelings Questionnaire (MFQ)-Long Form: This is designed for individuals aged 8 to 18, with cutoff scores of 27 for parent reports and 29 for youth self-reports.
• Patient Health Questionnaire: PHQ-9 is used for individuals aged 12 and older; cutoff scores of 10 indicate moderate depression, and 20 indicate severe depression.

Comprehensive Evaluation

A detailed clinical interview, incorporating input from parents, teachers, and caregivers, provides a comprehensive view of the child's functioning across various settings.

Differential Diagnosis

Accurately distinguishing depression from other conditions, such as anxiety disorders, attention-deficit/hyperactivity disorder (ADHD), and normative developmental variations, is essential for proper diagnosis and management.

No specific blood test or imaging study can diagnose depression. However, the evaluation of depression should consider medical conditions that may mimic depressive symptoms, including iron deficiency anemia, nutritional deficiencies, hypothyroidism, electrolyte imbalances, kidney, adrenal, and liver disorders, chronic infections, medication effects (such as propranolol), and substance use, such as alcohol.

Investigations to consider for ruling out differential diagnoses include:

• Complete blood count (CBC) and vitamin B12 levels.
• Electrolytes, including magnesium, calcium, and phosphate.
• Thyroid function tests, including thyroid-stimulating hormone (TSH), triiodothyronine (T3), and thyroxine (free T4).
• Liver and renal function tests, including blood urea nitrogen (BUN) and creatinine.
• Additional tests, including a urine toxicology screen, a blood alcohol level, an HIV test, a dexamethasone suppression test, and an adrenocorticotropic hormone (ACTH) stimulation test.

Treatment / Management

The primary goal of treatment is to achieve full remission and restore functional well-being. A biopsychosocial approach—integrating psychosocial interventions and pharmacotherapy when appropriate—is recommended.

Psychosocial Interventions

Psychotherapy is the first-line treatment for mild-to-moderate depression in adolescents.[32] Evidence-based interventions are mentioned below.

• Cognitive behavioral therapy or CBT: This therapy remains a cornerstone in the treatment of childhood depression. CBT has recently been adapted for digital platforms to enhance accessibility and engagement. A study by Christ et al demonstrated the effectiveness of internet-based CBT in reducing depressive symptoms among adolescents.[33]
• Interpersonal therapy or IPT: This therapy focuses on enhancing interpersonal relationships and improving communication skills.
• Family therapy: This aims to strengthen family support systems and improve problem-solving strategies within the household.
• Exercise and lifestyle modifications: Regular physical activity and structured sleep routines have been shown to improve depressive symptoms.[34]

Pharmacological Treatment

Pharmacotherapy

Selective serotonin reuptake inhibitors (SSRIs), such as fluoxetine, are approved for use in pediatric populations. Ongoing research continues to refine dosing strategies and assess the long-term safety of this treatment. A comprehensive analysis of antidepressants in children and adolescents has provided essential insights into their efficacy and safety profiles.[35] Notably, antidepressant response in adolescents differs from that of adults, with placebo effects being more pronounced in younger populations.[36]

• Selective serotonin reuptake inhibitors: SSRIs such as fluoxetine and escitalopram are approved by the US Food and Drug Administration (FDA) for the treatment of pediatric depression and have demonstrated efficacy in randomized controlled trials.[37]
• Serotonin-norepinephrine reuptake inhibitors or SNRIs: Venlafaxine may be considered a second-line option due to its potential adverse effects, including increased blood pressure and risk of suicidality.[38]

Integrated care models

Collaborative approaches that combine psychotherapy, pharmacotherapy, and family-based interventions have been shown to improve outcomes. Weisz et al emphasized the effectiveness of integrating evidence-based treatments into community settings to enhance both accessibility and effectiveness.[39]

Monitoring and Adverse Effects

Careful monitoring for suicidality, behavioral activation, and other adverse effects is essential during treatment. Common adverse effects of SSRIs include gastrointestinal discomfort, headaches, and increased agitation.[40]

Over the past 5 years, studies have shown that antidepressant medications—particularly SSRIs—are associated with adverse effects in pediatric populations, including gastrointestinal symptoms, insomnia, fatigue, and behavioral activation.[40] These findings underscore the need for vigilant monitoring when prescribing antidepressants to children and adolescents.

Suicidality and antidepressant medications

In 2004, a boxed warning was added to all antidepressants regarding the risk of suicidal thoughts and behaviors in children, adolescents, and young adults. This led to a decrease in prescription rates and increased clinician hesitation.[41][42] However, most meta-analyses and prospective controlled trials have not consistently replicated these findings.[43][44][45][46] Emerging data suggest that suicidality risk is influenced by factors such as specific medication choice, baseline suicidality, and underlying disorders.[47][48] Large cohort studies indicate that suicidality often peaks before treatment and declines after initiating SSRIs, underscoring the diagnostic complexity of these cases.[49][50]

Prevention Strategies

Proactive measures are vital in mitigating the onset of depression in children.

• Family-based interventions: Programs aimed at enhancing family communication and addressing parental mental health have proven effective in preventing depressive symptoms in children. Garber et al demonstrated that family-based preventive interventions significantly lower the incidence of depression in high-risk youth.[51]
• School-based programs: Implementing social-emotional learning curricula and offering mental health resources within schools can enhance resilience and facilitate early identification of at-risk students. A meta-analysis by Taylor et al found that school-based programs effectively promote social and emotional skills that protect against depression.[52]
• Policy initiatives: Advocacy efforts promoting policies to reduce harmful environmental exposures and regulate digital media use among youth are gaining momentum. For example, campaigns encouraging delayed smartphone access until at least age 14 aim to support healthy developmental outcomes.

Differential Diagnosis

Bipolar Depression

Clinicians must document at least one manic or hypomanic episode to diagnose bipolar affective disorder. In pediatric populations, the challenge lies in the fact that bipolar disorder often initially presents as a depressive episode during childhood or adolescence.

Adjustment Disorder

Symptoms of adjustment disorder emerge in response to a significant life event or stressor.

Substance Use Disorders

Withdrawal from substances such as amphetamines or cocaine, or intoxication from alcohol, can present with symptoms resembling depression. A diagnosis of depression as a concurrent disorder is appropriate if depressive symptoms persist independently or precede the onset of substance use.

Medical Conditions

Various medical conditions, such as multiple sclerosis, stroke, or hypothyroidism, can present with depressive symptoms.

Attention-Deficit Hyperactivity Disorder

ADHD may manifest with irritability and poor concentration, symptoms that overlap with those of pediatric depression..

Anxiety Disorder

This may present with difficulties in focusing, trouble falling asleep due to intrusive ruminative thoughts, and poor appetite—symptoms that can overlap with those of depression.

Prognosis

The duration of untreated depression is a critical predictor of outcomes. Early intervention can significantly reduce both symptom severity and the risk of recurrence.[53] Active treatment also shortens the duration of depressive episodes.[54] Remission rates for mild-to-moderate depression range from 60% to 90% within 1 year; however, relapse occurs in approximately 50% to 70% of cases.[55] 

Curry et al investigated recovery and recurrence rates following treatment for adolescent MDD in the Treatment for Adolescents with Depression Study (TADS). The study reported that 88% of adolescents achieved recovery within 5 years; however, 46% experienced a recurrence. Risk factors for recurrence included greater baseline severity and residual symptoms after treatment. These findings highlight the chronic and recurrent nature of adolescent MDD and emphasize the need for long-term monitoring and sustained intervention. This study offers valuable insights into the course of adolescent depression and informs strategies to prevent relapse.[61]

Adolescents with chronic or recurrent depression are at increased risk for persistent mood disorders in adulthood.[47] In specialist psychiatry settings, patients with MDD have long-term recurrence rates between 50% and 64%.[56] Relapse rates are notably higher following partial remission (67.6%) compared to complete remission (15.18%).[57] Children and adolescents who experience recurrent or chronic depression that extends into adulthood are more likely to endure significant disability and impairment.[58]

Complications

Pediatric depression has a complex clinical course and is frequently associated with serious complications that impact long-term developmental outcomes. Affected children and adolescents often struggle with academic underachievement, social withdrawal, and strained family relationships, all of which contribute to impaired psychosocial development.[59] When left untreated, depression in youth significantly increases the risk of substance use disorders, self-harm, and suicidal behaviors—suicide is now one of the leading causes of death among adolescents worldwide.[60] Early-onset depressive disorders are associated with increased chronicity and a higher risk of recurrence in adulthood, highlighting a developmental continuity that emphasizes the need for early and sustained intervention.[61]

Additionally, comorbid conditions such as anxiety, ADHD, and behavioral disorders often complicate the diagnostic process, resulting in delayed treatment and poorer outcomes.[62] Longitudinal cohort studies highlight the impact of biopsychosocial stressors and limited access to mental health services in sustaining these adverse trajectories.[56] These challenges underscore the urgent need for comprehensive, developmentally sensitive, and interdisciplinary approaches to diagnosis and treatment, with the goal of reducing long-term morbidity and promoting recovery across multiple life domains.

Deterrence and Patient Education

Effective prevention and education strategies for pediatric depression require an integrated, coordinated approach involving caregivers, schools, and primary care providers. Although the primary prevention of depressive disorders remains challenging, early identification of at-risk youth—such as those with a family history of mood disorders, exposure to trauma, or chronic medical conditions—is essential. Preventive interventions, including school-based resilience programs and parent training in emotion coaching, have shown promise in strengthening coping skills and reducing the incidence of major depressive episodes.

Patient and family education is fundamental to improving outcomes. Caregivers should be informed about the signs and symptoms of pediatric depression, including somatic complaints, academic decline, irritability, and social withdrawal. Emphasizing that depression is a medical illness, not a character flaw, can help reduce stigma and encourage treatment engagement. Families should be supported in maintaining regular routines, promoting healthy sleep and screen habits, and fostering open communication. For adolescents, it is important to address the risks of substance use, online bullying, and social isolation. Clinicians should also educate families about the safety and effectiveness of treatment options, including CBT and pharmacotherapy, reassuring them that most youth respond well to evidence-based care.

Importantly, ongoing psychoeducation should emphasize the risk of recurrence and the importance of medication adherence (when applicable), regular follow-up appointments, and crisis planning. Collaborating with schools to develop care plans and teaching children adaptive skills—such as emotion regulation and problem-solving—further supports long-term well-being.

Enhancing Healthcare Team Outcomes

Pediatric depression is often underdiagnosed and undertreated. A multidisciplinary team of healthcare providers, including psychiatrists, psychologists, primary care providers, and school-based counselors, is essential for comprehensive management. Advocating for mental health awareness and reducing stigma remains a critical public health priority.[63] Admission to an inpatient unit should be considered when depression is severe or the child’s safety is at risk. Pediatricians and mental health professionals must consistently promote and advocate for the mental health of this population, raise awareness, and work to reduce stigma.[62]

The landscape of childhood depression is continually evolving, shaped by technological advances, environmental influences, and societal shifts. Staying current with research and adopting a multifaceted approach to assessment, treatment, and prevention is essential. By integrating evidence-based practices and advocating for systemic change, we can better support the mental health and well-being of our youngest populations.

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Hawes MT, Szenczy AK, Klein DN, Hajcak G, Nelson BD. Increases in depression and anxiety symptoms in adolescents and young adults during the COVID-19 pandemic. Psychol Med. 2022 Oct;52(14):3222-3230. [PMC free article: PMC7844180] [PubMed: 33436120]

2.

Laceulle OM, Veenstra R, Vollebergh WAM, Ormel J. Sequences of maladaptation: Preadolescent self-regulation, adolescent negative social interactions, and young adult psychopathology. Dev Psychopathol. 2019 Feb;31(1):279-292. [PubMed: 29229016]

3.

Kappelmann N, Arloth J, Georgakis MK, Czamara D, Rost N, Ligthart S, Khandaker GM, Binder EB. Dissecting the Association Between Inflammation, Metabolic Dysregulation, and Specific Depressive Symptoms: A Genetic Correlation and 2-Sample Mendelian Randomization Study. JAMA Psychiatry. 2021 Feb 01;78(2):161-170. [PMC free article: PMC7577200] [PubMed: 33079133]

4.

Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium. Electronic address: andrew.mcintosh@ed.ac.uk; Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium. Trans-ancestry genome-wide study of depression identifies 697 associations implicating cell types and pharmacotherapies. Cell. 2025 Feb 06;188(3):640-652.e9. [PMC free article: PMC11829167] [PubMed: 39814019]

5.

Hankin BL, Nederhof E, Oppenheimer CW, Jenness J, Young JF, Abela JR, Smolen A, Ormel J, Oldehinkel AJ. Differential susceptibility in youth: evidence that 5-HTTLPR x positive parenting is associated with positive affect 'for better and worse'. Transl Psychiatry. 2011 Oct 04;1(10):e44. [PMC free article: PMC3309487] [PubMed: 22833190]

6.

Yang XJ, Zhang LB, Wang LL, Deng H, Li YL, Zhao RJ, Xu JY, Yang YC, Zhou SJ. Status and risk factors for depression, anxiety, and insomnia symptoms among adolescents in the post-pandemic era. BMC Public Health. 2025 Feb 05;25(1):471. [PMC free article: PMC11800650] [PubMed: 39910549]

7.

Neshat-Doost HT, Taghavi MR, Moradi AR, Yule W, Dalgleish T. Memory for emotional trait adjectives in clinically depressed youth. J Abnorm Psychol. 1998 Nov;107(4):642-50. [PubMed: 9830251]

8.

LeMoult J, Humphreys KL, Tracy A, Hoffmeister JA, Ip E, Gotlib IH. Meta-analysis: Exposure to Early Life Stress and Risk for Depression in Childhood and Adolescence. J Am Acad Child Adolesc Psychiatry. 2020 Jul;59(7):842-855. [PMC free article: PMC11826385] [PubMed: 31676392]

9.

Hoffman KB, Cole DA, Martin JM, Tram J, Seroczynski AD. Are the discrepancies between self- and others' appraisals of competence predictive or reflective of depressive symptoms in children and adolescents: a longitudinal study, Part II. J Abnorm Psychol. 2000 Nov;109(4):651-62. [PubMed: 11195989]

10.

Cole DA. Preliminary support for a competency-based model of depression in children. J Abnorm Psychol. 1991 May;100(2):181-90. [PubMed: 2040769]

11.

Oppenheimer CW, Technow J, Hankin BL, Young JF, Abela JR. Rumination and Excessive Reassurance Seeking: Investigation of the Vulnerability Model and Specificity to Depression. Int J Cogn Ther. 2012 Sep 01;5(3):254-267. [PMC free article: PMC3920592] [PubMed: 24527172]

12.

Gruber J, Prinstein MJ, Clark LA, Rottenberg J, Abramowitz JS, Albano AM, Aldao A, Borelli JL, Chung T, Davila J, Forbes EE, Gee DG, Hall GCN, Hallion LS, Hinshaw SP, Hofmann SG, Hollon SD, Joormann J, Kazdin AE, Klein DN, La Greca AM, Levenson RW, MacDonald AW, McKay D, McLaughlin KA, Mendle J, Miller AB, Neblett EW, Nock M, Olatunji BO, Persons JB, Rozek DC, Schleider JL, Slavich GM, Teachman BA, Vine V, Weinstock LM. Mental health and clinical psychological science in the time of COVID-19: Challenges, opportunities, and a call to action. Am Psychol. 2021 Apr;76(3):409-426. [PMC free article: PMC7873160] [PubMed: 32772538]

13.

Rao U, Hammen CL, Poland RE. Risk markers for depression in adolescents: sleep and HPA measures. Neuropsychopharmacology. 2009 Jul;34(8):1936-45. [PMC free article: PMC2697268] [PubMed: 19262465]

14.

Tesler N, Gerstenberg M, Franscini M, Jenni OG, Walitza S, Huber R. Increased frontal sleep slow wave activity in adolescents with major depression. Neuroimage Clin. 2016;10:250-6. [PMC free article: PMC4712324] [PubMed: 26870661]

15.

Carpenter JS, Robillard R, Hermens DF, Naismith SL, Gordon C, Scott EM, Hickie IB. Sleep-wake profiles and circadian rhythms of core temperature and melatonin in young people with affective disorders. J Psychiatr Res. 2017 Nov;94:131-138. [PubMed: 28711776]

16.

Minges KE, Whittemore R, Weinzimer SA, Irwin ML, Redeker NS, Grey M. Correlates of overweight and obesity in 5529 adolescents with type 1 diabetes: The T1D Exchange Clinic Registry. Diabetes Res Clin Pract. 2017 Apr;126:68-78. [PMC free article: PMC5401652] [PubMed: 28214669]

17.

Forbes MK, Tackett JL, Markon KE, Krueger RF. Beyond comorbidity: Toward a dimensional and hierarchical approach to understanding psychopathology across the life span. Dev Psychopathol. 2016 Nov;28(4pt1):971-986. [PMC free article: PMC5098269] [PubMed: 27739384]

18.

Kirilly E, Gonda X, Juhász G, Bagdy G. [Anxiogenic and depressogenic side-effects of non-psychiatric drugs]. Orv Hetil. 2013 Aug 25;154(34):1327-36. [PubMed: 23955968]

19.

Celano CM, Freudenreich O, Fernandez-Robles C, Stern TA, Caro MA, Huffman JC. Depressogenic effects of medications: a review. Dialogues Clin Neurosci. 2011;13(1):109-25. [PMC free article: PMC3181967] [PubMed: 21485751]

20.

Richmond-Rakerd LS, D'Souza S, Milne BJ, Andersen SH. Suicides, drug poisonings, and alcohol-related deaths cluster with health and social disadvantage in 4.1 million citizens from two nations. Psychol Med. 2024 Jun;54(8):1610-1619. [PMC free article: PMC12588360] [PubMed: 38112104]

21.

Keles S, Idsoe T. Six- and Twelve-Month Follow-up Results of a Cluster Randomized Controlled Trial of a CBT-Based Group Course. Prev Sci. 2021 May;22(4):409-418. [PubMed: 32889703]

22.

Li M, Mustillo S. Linking Mother and Offspring Depressive Symptoms: The mediating role of child appearance contingent self-worth. J Affect Disord. 2020 Aug 01;273:113-121. [PubMed: 32421591]

23.

Shirk SR, Gudmundsen GR, Burwell RA. Links among attachment-related cognitions and adolescent depressive symptoms. J Clin Child Adolesc Psychol. 2005 Mar;34(1):172-81. [PubMed: 15677291]

24.

Hammen C. Self-cognitions, stressful events, and the prediction of depression in children of depressed mothers. J Abnorm Child Psychol. 1988 Jun;16(3):347-60. [PubMed: 3403815]

25.

Lewinsohn PM, Rohde P, Seeley JR. Major depressive disorder in older adolescents: prevalence, risk factors, and clinical implications. Clin Psychol Rev. 1998 Nov;18(7):765-94. [PubMed: 9827321]

26.

Hyde JS, Mezulis AH, Abramson LY. The ABCs of depression: integrating affective, biological, and cognitive models to explain the emergence of the gender difference in depression. Psychol Rev. 2008 Apr;115(2):291-313. [PubMed: 18426291]

27.

Curtis M, Flournoy JC, Kandala S, Sanders AFP, Harms MP, Omary A, Somerville LH, Barch DM. Disentangling the unique contributions of age, pubertal stage, and pubertal hormones to brain structure in childhood and adolescence. Dev Cogn Neurosci. 2024 Dec;70:101473. [PMC free article: PMC11609316] [PubMed: 39546965]

28.

Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL, editors. Global Burden of Disease and Risk Factors. The International Bank for Reconstruction and Development / The World Bank; Washington (DC): 2006. [PubMed: 21250374]

29.

Ruchkin V, Sukhodolsky DG, Vermeiren R, Koposov RA, Schwab-Stone M. Depressive symptoms and associated psychopathology in urban adolescents: a cross-cultural study of three countries. J Nerv Ment Dis. 2006 Feb;194(2):106-13. [PubMed: 16477188]

30.

Siu AL., US Preventive Services Task Force. Screening for Depression in Children and Adolescents: US Preventive Services Task Force Recommendation Statement. Pediatrics. 2016 Mar;137(3):e20154467. [PubMed: 26908686]

31.

Goff SL, Brooks B, DaCosta MC, DeCou E, Wallace K, Sule S, Bromberg J, Vernacchio L, Walter HJ. Considerations for Behavioral Health Integration Program Implementation in Pediatric Primary Care Settings: A Qualitative Study. Acad Pediatr. 2023 Oct 27; [PubMed: 39491130]

32.

Schramm E, Elsaesser M, Müller J, Kwarteng NA, Evrenoglou T, Cuijpers P, Orestis E, Klein DN, Keller MB, Furukawa TA, Nikolakopoulou A. Efficacy of psychotherapy versus pharmacotherapy, or their combination, in chronic depression: study protocol for a systematic review and network meta-analysis using aggregated and individual patient data. BMJ Open. 2025 Feb 19;15(2):e089356. [PMC free article: PMC11840898] [PubMed: 39971604]

33.

Christ C, Schouten MJ, Blankers M, van Schaik DJ, Beekman AT, Wisman MA, Stikkelbroek YA, Dekker JJ. Internet and Computer-Based Cognitive Behavioral Therapy for Anxiety and Depression in Adolescents and Young Adults: Systematic Review and Meta-Analysis. J Med Internet Res. 2020 Sep 25;22(9):e17831. [PMC free article: PMC7547394] [PubMed: 32673212]

34.

Pascoe M, Bailey AP, Craike M, Carter T, Patten R, Stepto N, Parker A. Physical activity and exercise in youth mental health promotion: a scoping review. BMJ Open Sport Exerc Med. 2020;6(1):e000677. [PMC free article: PMC7010991] [PubMed: 32095272]

35.

Zhou X, Cipriani A, Zhang Y, Cuijpers P, Hetrick SE, Weisz JR, Pu J, Del Giovane C, Furukawa TA, Barth J, Coghill D, Leucht S, Yang L, Ravindran AV, Xie P. Comparative efficacy and acceptability of antidepressants, psychological interventions, and their combination for depressive disorder in children and adolescents: protocol for a network meta-analysis. BMJ Open. 2017 Aug 11;7(8):e016608. [PMC free article: PMC5629731] [PubMed: 28801423]

36.

Locher C, Koechlin H, Zion SR, Werner C, Pine DS, Kirsch I, Kessler RC, Kossowsky J. Efficacy and Safety of Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, and Placebo for Common Psychiatric Disorders Among Children and Adolescents: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2017 Oct 01;74(10):1011-1020. [PMC free article: PMC5667359] [PubMed: 28854296]

37.

Türkmen C, Machunze N, Lee AM, Bougelet E, Ludin NM, de Cates AN, Vollstädt-Klein S, Bach P, Kiefer F, Burdzovic Andreas J, Kamphuis J, Schoevers RA, Emslie GJ, Hetrick SE, Viechtbauer W, van Dalfsen JH. Systematic Review and Meta-Analysis: The Association Between Newer-Generation Antidepressants and Insomnia in Children and Adolescents With Major Depressive Disorder. J Am Acad Child Adolesc Psychiatry. 2025 Oct;64(10):1148-1164. [PubMed: 39828036]

38.

Zhou X, Teng T, Zhang Y, Del Giovane C, Furukawa TA, Weisz JR, Li X, Cuijpers P, Coghill D, Xiang Y, Hetrick SE, Leucht S, Qin M, Barth J, Ravindran AV, Yang L, Curry J, Fan L, Silva SG, Cipriani A, Xie P. Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis. Lancet Psychiatry. 2020 Jul;7(7):581-601. [PMC free article: PMC7303954] [PubMed: 32563306]

39.

Weisz JR, Kuppens S, Ng MY, Eckshtain D, Ugueto AM, Vaughn-Coaxum R, Jensen-Doss A, Hawley KM, Krumholz Marchette LS, Chu BC, Weersing VR, Fordwood SR. What five decades of research tells us about the effects of youth psychological therapy: A multilevel meta-analysis and implications for science and practice. Am Psychol. 2017 Feb-Mar;72(2):79-117. [PubMed: 28221063]

40.

Strawn JR, Mills JA, Poweleit EA, Ramsey LB, Croarkin PE. Adverse Effects of Antidepressant Medications and their Management in Children and Adolescents. Pharmacotherapy. 2023 Jul;43(7):675-690. [PMC free article: PMC10378577] [PubMed: 36651686]

41.

Hammad TA, Laughren TP, Racoosin JA. Suicide rates in short-term randomized controlled trials of newer antidepressants. J Clin Psychopharmacol. 2006 Apr;26(2):203-7. [PubMed: 16633153]

42.

Gibbons RD, Brown CH, Hur K, Davis J, Mann JJ. Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine. Arch Gen Psychiatry. 2012 Jun;69(6):580-7. [PMC free article: PMC3367101] [PubMed: 22309973]

43.

Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher B, Pincus HA, Ren L, Brent DA. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA. 2007 Apr 18;297(15):1683-96. [PubMed: 17440145]

44.

Cipriani A, Zhou X, Del Giovane C, Hetrick SE, Qin B, Whittington C, Coghill D, Zhang Y, Hazell P, Leucht S, Cuijpers P, Pu J, Cohen D, Ravindran AV, Liu Y, Michael KD, Yang L, Liu L, Xie P. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. Lancet. 2016 Aug 27;388(10047):881-90. [PubMed: 27289172]

45.

Hetrick SE, McKenzie JE, Cox GR, Simmons MB, Merry SN. Newer generation antidepressants for depressive disorders in children and adolescents. Cochrane Database Syst Rev. 2012 Nov 14;11(11):CD004851. [PMC free article: PMC8786271] [PubMed: 23152227]

46.

Strawn JR, Mills JA, Schroeder H, Mossman SA, Varney ST, Ramsey LB, Poweleit EA, Desta Z, Cecil K, DelBello MP. Escitalopram in Adolescents With Generalized Anxiety Disorder: A Double-Blind, Randomized, Placebo-Controlled Study. J Clin Psychiatry. 2020 Aug 25;81(5) [PMC free article: PMC7504974] [PubMed: 32857933]

47.

Brent DA, Emslie GJ, Clarke GN, Asarnow J, Spirito A, Ritz L, Vitiello B, Iyengar S, Birmaher B, Ryan ND, Zelazny J, Onorato M, Kennard B, Mayes TL, Debar LL, McCracken JT, Strober M, Suddath R, Leonard H, Porta G, Keller MB. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. Am J Psychiatry. 2009 Apr;166(4):418-26. [PMC free article: PMC3593721] [PubMed: 19223438]

48.

Sharma T, Guski LS, Freund N, Gøtzsche PC. Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports. BMJ. 2016 Jan 27;352:i65. [PMC free article: PMC4729837] [PubMed: 26819231]

49.

Lagerberg T, Fazel S, Sjölander A, Hellner C, Lichtenstein P, Chang Z. Selective serotonin reuptake inhibitors and suicidal behaviour: a population-based cohort study. Neuropsychopharmacology. 2022 Mar;47(4):817-823. [PMC free article: PMC8882171] [PubMed: 34561608]

50.

Molero Y, Zetterqvist J, Binswanger IA, Hellner C, Larsson H, Fazel S. Medications for Alcohol and Opioid Use Disorders and Risk of Suicidal Behavior, Accidental Overdoses, and Crime. Am J Psychiatry. 2018 Oct 01;175(10):970-978. [PMC free article: PMC6169735] [PubMed: 30068260]

51.

Garber J, Frankel SA, Herrington CG. Developmental Demands of Cognitive Behavioral Therapy for Depression in Children and Adolescents: Cognitive, Social, and Emotional Processes. Annu Rev Clin Psychol. 2016;12:181-216. [PMC free article: PMC5441981] [PubMed: 27019397]

52.

Taylor RD, Oberle E, Durlak JA, Weissberg RP. Promoting Positive Youth Development Through School-Based Social and Emotional Learning Interventions: A Meta-Analysis of Follow-Up Effects. Child Dev. 2017 Jul;88(4):1156-1171. [PubMed: 28685826]

53.

Ghio L, Gotelli S, Marcenaro M, Amore M, Natta W. Duration of untreated illness and outcomes in unipolar depression: a systematic review and meta-analysis. J Affect Disord. 2014 Jan;152-154:45-51. [PubMed: 24183486]

54.

Hung CI, Liu CY, Yang CH. Untreated duration predicted the severity of depression at the two-year follow-up point. PLoS One. 2017;12(9):e0185119. [PMC free article: PMC5608308] [PubMed: 28934289]

55.

van Tuijl LA, Glashouwer KA, Elgersma HJ, Bockting CLH, Penninx BWJH, de Jong PJ. Depression recurrence after recovery: Prognostic value of implicit and explicit self-depressed associations. Behav Res Ther. 2018 Aug;107:76-82. [PubMed: 29890307]

56.

Patton GC, Coffey C, Romaniuk H, Mackinnon A, Carlin JB, Degenhardt L, Olsson CA, Moran P. The prognosis of common mental disorders in adolescents: a 14-year prospective cohort study. Lancet. 2014 Apr 19;383(9926):1404-11. [PubMed: 24439298]

57.

Pintor L, Gastó C, Navarro V, Torres X, Fañanas L. Relapse of major depression after complete and partial remission during a 2-year follow-up. J Affect Disord. 2003 Feb;73(3):237-44. [PubMed: 12547292]

58.

Birmaher B, Ryan ND, Williamson DE, Brent DA, Kaufman J. Childhood and adolescent depression: a review of the past 10 years. Part II. J Am Acad Child Adolesc Psychiatry. 1996 Dec;35(12):1575-83. [PubMed: 8973063]

59.

Thapar A, Collishaw S, Pine DS, Thapar AK. Depression in adolescence. Lancet. 2012 Mar 17;379(9820):1056-67. [PMC free article: PMC3488279] [PubMed: 22305766]

60.

Ruch DA, Sheftall AH, Schlagbaum P, Rausch J, Campo JV, Bridge JA. Trends in Suicide Among Youth Aged 10 to 19 Years in the United States, 1975 to 2016. JAMA Netw Open. 2019 May 03;2(5):e193886. [PMC free article: PMC6537827] [PubMed: 31099867]

61.

Curry J, Silva S, Rohde P, Ginsburg G, Kratochvil C, Simons A, Kirchner J, May D, Kennard B, Mayes T, Feeny N, Albano AM, Lavanier S, Reinecke M, Jacobs R, Becker-Weidman E, Weller E, Emslie G, Walkup J, Kastelic E, Burns B, Wells K, March J. Recovery and recurrence following treatment for adolescent major depression. Arch Gen Psychiatry. 2011 Mar;68(3):263-9. [PMC free article: PMC3074362] [PubMed: 21041606]

62.

Birmaher B, Brent D, AACAP Work Group on Quality Issues. Bernet W, Bukstein O, Walter H, Benson RS, Chrisman A, Farchione T, Greenhill L, Hamilton J, Keable H, Kinlan J, Schoettle U, Stock S, Ptakowski KK, Medicus J. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry. 2007 Nov;46(11):1503-26. [PubMed: 18049300]

63.

Zhou SJ, Zhang LG, Wang LL, Guo ZC, Wang JQ, Chen JC, Liu M, Chen X, Chen JX. Prevalence and socio-demographic correlates of psychological health problems in Chinese adolescents during the outbreak of COVID-19. Eur Child Adolesc Psychiatry. 2020 Jun;29(6):749-758. [PMC free article: PMC7196181] [PubMed: 32363492]

Disclosure: Veeraraghavan Iyer declares no relevant financial relationships with ineligible companies.

Disclosure: Yusra Azhar declares no relevant financial relationships with ineligible companies.

Disclosure: Sunny Aslam declares no relevant financial relationships with ineligible companies.